Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 17

Results For "food"

1471 News Found

Lupin launches Bumetanide Injection USP in US
News | November 20, 2024

Lupin launches Bumetanide Injection USP in US

Bumetanide Injection USP (RLD Bumex) had an estimated annual sale of USD 20 million in the US


Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications
News | November 16, 2024

Ecovyst launches AlphaCat advanced silicas products for biocatalysis applications

Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential


Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America
Supply Chain | November 16, 2024

Univar Solutions becomes exclusive distributor of SD Head USA Pharmaceutical excipients in North America

Univar Solutions' pharmaceutical ingredients portfolio will be strengthened by the addition of a broad range of cellulose ethers and other excipient solutions


USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
Drug Approval | November 16, 2024

USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency

Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters


Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr
News | November 11, 2024

Zydus Wellness Q2 FY25 sales up 12% at Rs. 490.7 Cr

Net profit for the quarter grew by 254.2 per cent and stood at Rs. 20.9 crore


Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules
Drug Approval | November 11, 2024

Alembic receives USFDA final approval for Diltiazem Hydrochloride ER capsules

Diltiazem Hydrochloride Extended-Release Capsules USP are indicated for the treatment of hypertension


USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI
News | November 11, 2024

USFDA classifies Biocon Biologics’ Biocon Park in Bengaluru as VAI

The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants


Granules India’s Unit V facility secures USFDA EIR with NAI status
Drug Approval | November 10, 2024

Granules India’s Unit V facility secures USFDA EIR with NAI status

The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit


Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr
News | November 10, 2024

Vimta Labs reports Q2 FY25 PAT at Rs. 17 Cr

Q2 FY25 Total Income was at Rs. 85.4 crore